drugset / Trial / NCT07102901
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2025-09-05
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |
| Subject | SHR-A1904 | Unknown | — | — |
| Subject | SHR2554 | Small molecule | — | Oral |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |